| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10213415 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US8609709 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US7786158 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US8691860 | ALLERGAN HOLDINGS | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9115091 | ALLERGAN HOLDINGS | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US7741356 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
May, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8344011 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US8772325 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US9205076 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US9700542 | ALLERGAN HOLDINGS | Compounds as opioid receptor modulators |
Mar, 2025
(1 year, 5 months from now) | |
| US9364489 | ALLERGAN HOLDINGS | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9789125 | ALLERGAN HOLDINGS | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9675587 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US10188632 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11090291 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11229627 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11007179 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11160792 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11311516 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
| US11484527 | ALLERGAN HOLDINGS | Opioid receptor modulator dosage formulations |
Mar, 2033
(9 years from now) | |
Viberzi is owned by Allergan Holdings.
Viberzi contains Eluxadoline.
Viberzi has a total of 20 drug patents out of which 0 drug patents have expired.
Viberzi was authorised for market use on 27 May, 2015.
Viberzi is available in tablet;oral dosage forms.
Viberzi can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food.
The generics of Viberzi are possible to be released after 14 March, 2033.
Drugs and Companies using ELUXADOLINE ingredient
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...
Dosage: TABLET;ORAL
VIBERZI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic